RAD1

Across TCGA pan-cancer cohorts, RAD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAD1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RAD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAD1 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where RAD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.722	0.288	.001	21	view →
PDAC	DFS	Median	III,IV	0.962	0.175	.017	14	view →
LUAD	DFS	Median	All	1.000	0.891	.014	11	view →
CCRCC	OS	Median	II,III,IV	0.485	1.000	.036	5	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.761	.014	4	view →
HNSC	OS	Quartile	All	0.741	0.937	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAD1–GBM (OS)

Open the GBM breakdown →